Lonergan, Mike
Dicker, Alison J.
Crichton, Megan L.
Keir, Holly R.
Van Dyke, Melissa K.
Mullerova, Hana
Miller, Bruce E.
Tal-Singer, Ruth
Chalmers, James D.
Funding for this research was provided by:
GlaxoSmithKline (TARDIS)
Article History
Received: 27 February 2020
Accepted: 25 June 2020
First Online: 1 July 2020
Ethics approval and consent to participate
: The study was approved by the local research ethics committee approval number 13/ES/0030. All patients gave written informed consent to participate.
: Not applicable.
: ML, AJD, MLC, HRK report no real or perceived conflicts of interest relating to this manuscript. MKVD and HM were employees of Glaxosmithkline during the study period. BEM is an employee and shareholder of Glaxosmithkline. RTS was an employee and shareholder of Glaxosmithkline during the study period. JDC reports receiving a grant from Glaxosmithkline for this work; additional research grants for COPD studies from Glaxosmithkline, Boehringer-Ingelheim, Astrazeneca and Pfizer, additional research grants for Bronchiectasis research studies from Bayer Healthcare and Grifols and personal fees from Napp and Aradigm corporation.